Loading...
Market
Will Moderna's 2025 revenue exceed $2 billion?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Moderna's official financial statements and earnings reports
Story
Moderna Lowers 2025 Revenue Forecast to $1.5B–$2.5B; Shares Plunge 20% Pre-Market
Jan 13, 2025, 12:31 PM
Moderna Inc. lowered its 2025 revenue forecast to a range of $1.5 billion to $2.5 billion, down from previous estimates of $2.5 billion to $3.5 billion and below analysts' expectations of $2.95 billion, due to slower-than-expected demand for its COVID-19 and RSV vaccines. The company also reported 2024 product sales of $3.0 to $3.1 billion and an ending cash balance of approximately $9.5 billion. In response to the reduced revenue outlook, Moderna plans to reduce its 2025 cash cost expenses by $1 billion and intends to implement additional cost reductions of $500 million in 2026. CEO Stéphane Bancel highlighted the company's focus on driving growth, with a pipeline of 10 vaccines. Following the announcement, Moderna's stock plunged up to 20% in pre-market trading, reaching its lowest levels since April 2020.
View original story
Similar markets
More than $7B • 25%
$5B to $6B • 25%
Less than $5B • 25%
$6B to $7B • 25%
3-4 • 25%
5-6 • 25%
More than 6 • 25%
0-2 • 25%
Increase by 10% to 20% • 25%
Increase by less than 10% • 25%
Decrease • 25%
Increase by more than 20% • 25%
More than $2 billion • 25%
$1 billion to $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%